Lanjia Lin - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Lanjia Lin

Showing results (11-20 of 13) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 13 results.

Journal of Hepatology|May 15, 2018

96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infectionKosh Agarwal, Maurizia Brunetto, Wai Kay Seto, et al.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 25, 2020

Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of CareSusan A Olender, Katherine K Perez, Alan S Go, et al.

Journal of Hepatology|July 25, 2020

aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitisRong Fan, George Papatheodoridis, Jian Sun, et al.

Pageof 2

Search research articles

Showing results (11-20 of 13) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 13 results.

Journal of Hepatology|May 15, 2018

96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infectionKosh Agarwal, Maurizia Brunetto, Wai Kay Seto, et al.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 25, 2020

Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of CareSusan A Olender, Katherine K Perez, Alan S Go, et al.

Journal of Hepatology|July 25, 2020

aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitisRong Fan, George Papatheodoridis, Jian Sun, et al.

Pageof 2